Abstract
Recent correspondence to Clinical Chemistry (1)(2) addressed the performance of the second generation Tacrolimus assay for the IMx analyzer (Abbott Diagnostics), with the former letter identifying nonequivalence in results from its predecessor and the latter considering performance approaching the lower limits of detection. Our own published results (3) have considered these points, and we report here our additional experience. In their comparison of the second- vs the first-generation assays, Garg et al. (1) described comparable coefficients of variation (CVs), but this is not the case when identical control samples are used in each assay at low concentrations (≤5 μg/L), e.g., 14.2% vs 42.4% at 4.2 μg of tacrolimus per liter of blood (1). In common with previous findings (3)(4)(5), Garg et al. (1) reported lower values with the second-generation assay using 36 samples of undefined origin. The slopes and intercepts reported for these various comparisons differed (as did the comparison methods applied), but Garg et al. (1) did not relate …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
